Aspirin's Heart Benefit in Kidney Patients Unclear

Adults with chronic kidney disease and no prior heart disease saw fewer events on aspirin but more major bleeding.

Updated on Nov. 6, 2026 in Heart Disease

Isometric editorial illustration of a balance scale with a heart-shaped weight and a teardrop weight on opposing pans, depicting an unresolved trade-off.
A new analysis of the ATTACK trial found inconclusive evidence that daily low-dose aspirin prevents first heart and vascular events in adults with chronic kidney disease. AI Illustration. Upload story photo >

The ATTACK trial found inconclusive evidence that low-dose aspirin reduces first atherosclerotic cardiovascular events in adults with chronic kidney disease who have no prior heart or vascular disease. Results were presented at the 2026 ASN Kidney Week in Denver, Colorado.

Why it matters

Adults with chronic kidney disease face elevated cardiovascular risk, so whether daily aspirin meaningfully prevents a first heart or vascular event matters for prevention decisions. The trial's mixed signal, with a lower event rate in the aspirin group but more major bleeding, shows why the balance of benefit and harm remains unsettled.

The ATTACK trial randomized 4,633 adults with chronic kidney disease (stages G1-4) and no prior cardiovascular disease to 75 mg aspirin or no aspirin, with a mean follow-up of 3.1 years. The open-label design and the small number of primary events mean the evidence is inconclusive, and further trials or a pooled meta-analysis are needed.

The players

ASN Kidney Week

The annual meeting of the American Society of Nephrology, where kidney researchers and clinicians present major new findings on kidney disease and its complications.

The details

The trial used an open-label, multicenter design in which patients were randomly assigned to either daily 75 mg aspirin or no aspirin. Aspirin works by blocking platelets from clumping, which can reduce the formation of arterial clots that trigger heart attacks and strokes, but the same effect raises the risk of bleeding. In this trial, the primary endpoint was time to first major cardiovascular event, and the aspirin group had both fewer of those events and more major bleeds, including intracranial bleeds.

Timeline

  1. Patient randomization for the trial began in March 2019 and ended in December 2023.

  2. Results were presented in 2026 at ASN Kidney Week in Denver, Colorado.

Health Landscape

Aspirin is widely used to prevent cardiovascular events, but its benefit in people without prior heart disease has been repeatedly weighed against bleeding risk. Chronic kidney disease is strongly associated with cardiovascular disease, so this population has long been a focus of prevention research, and the ATTACK results add to an evidence base that still lacks a clear answer.

If you have chronic kidney disease, this trial suggests aspirin's benefit for preventing a first heart event is uncertain and comes with a real bleeding risk, so it is worth raising with your doctor before making any change to your medications. Anyone with kidney disease should keep their cardiovascular risk factors, such as blood pressure and cholesterol, under regular review with their care team.

The takeaway

The big insight is that aspirin for first-event prevention in kidney disease is still an open question, with fewer events but more bleeding in this trial. A practical step is to ask your physician how your individual cardiovascular and bleeding risk should shape any aspirin decision.

Further reading

For more on the cardiovascular risks tied to kidney health, explore our Heart Disease coverage.

Source note: This article includes information reported by Derm Immuno Today.